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Introduction {#sec001}
============

Overexpression of BCL2 (B-cell lymphoma 2), a mitochondrial membrane protein has been observed in several haematological malignancies due to genetic and epigenetic mechanisms resulting in evasion of apoptosis, giving the malignant cells a longer life span and survival benefits at times of nutrient deficiency, hypoxia and growth factor deprivation \[[@pone.0236338.ref001]--[@pone.0236338.ref003]\]. Estimation of level of BCL2 along with other anti-apoptotic genes are essential to avail efficient treatment-options by R-CHOP (Regimen of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone and Rituximab) or Venetoclax in different haematological malignancies \[[@pone.0236338.ref004], [@pone.0236338.ref005]\]. By visualization of chromosomal aberrations using karyotyping or FISH (Fluorescence in-situ Hybridization), BCL2 levels can be inferred indirectly \[[@pone.0236338.ref006]\]. Detection of expression of BCL2 protein by immunohistochemistry, a standard pathological testing procedure for DLBCL, has not been adopted in the clinics for bone marrow tissues of liquid cancers due to sample inconsistency and challenging procedure of capturing low concentrations of biomarkers \[[@pone.0236338.ref007]\]. Western blotting, for the very nature of the method, cannot be adopted for high throughput pathological testing. ELISA, for detection of BCL2 in human plasma remains limited since only one splice isoform of the mitochondrial membrane protein is available in soluble form, thus bringing down the effectiveness of the assay \[[@pone.0236338.ref008]\]. BCL2 at the mRNA level can be determined without ambiguity by next generation sequencing \[[@pone.0236338.ref009]\], NanoString \[[@pone.0236338.ref010]\] and microarray \[[@pone.0236338.ref011]\], though increasing time and expense of pathological testing. In clinical trials relative quantification by qPCR (Quantitative Polymerase Chain Reaction)can be successfully used due to the availability of appropriate controls in untreated or normal groups \[[@pone.0236338.ref012], [@pone.0236338.ref013]\]. Although being time and cost-effective, it suffers misinterpretation in pathological setting since the relative quantification depends only on the RG (Reference Gene) used due to the absence of normal samples.

Normalization with a RG which shows varying expression across samples can often lead to wrong conclusions as seen with the use of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) as RG in gene expression studies of pulmonary tuberculosis \[[@pone.0236338.ref014]\] and CD8+ T-cells under inactivated or activated condition \[[@pone.0236338.ref015]\]. Similarly, ABL proto-oncogene 1 (ABL1), the recommended RG for gene expression studies with leukemic patients \[[@pone.0236338.ref016]\] was found to have extremely low expression in neutrophils \[[@pone.0236338.ref017]\] making it unsuitable as RG for the specific case. Such discrepancies have prompted researchers to analyze gene expression across multiple tissues \[[@pone.0236338.ref018]\] or pan-cancer database like TCGA \[[@pone.0236338.ref019]\] to propose normalization factors using multiple RG candidates.

This study, through a systematic review of literature in haematological malignancies concluded that mostly conventionally used "house-keeping" genes are still being deployed ([S1 Table](#pone.0236338.s001){ref-type="supplementary-material"} and [S1 Fig](#pone.0236338.s010){ref-type="supplementary-material"}) despite their varied expression based on cell type, developmental stage and experimental conditions \[[@pone.0236338.ref020]\] with rare exceptions \[[@pone.0236338.ref021], [@pone.0236338.ref022]\]. None of the 43 genes thus identified could be used to relatively quantify BCL2 as molecular diagnostics since compared to the FPKM (Fragments Per Kilobase of transcript per Million mapped reads) value of the anti-apoptotic genes across 4 databases ([S2 Fig](#pone.0236338.s011){ref-type="supplementary-material"}), most of the RGs from the literature are not only higher, but also varied significantly ([S3](#pone.0236338.s012){ref-type="supplementary-material"} and [S4](#pone.0236338.s013){ref-type="supplementary-material"} Figs) with few exceptions. Inspired by genome wide search for RGs from publicly available RNA-seq or microarray data in human and other organisms \[[@pone.0236338.ref023]--[@pone.0236338.ref025]\], we report here a set of novel candidate RGs obtained from an unbiased search of \>60,000 genes in haematological malignancies to be used to normalize BCL2 and other anti-apoptotic genes in qPCR as molecular diagnostics.

Materials and methods {#sec002}
=====================

Ethics statement {#sec003}
----------------

The study was performed in compliance with ethical practices and was approved by Narayana Health Academics Ethics Committee, Narayana Health Hospitals (Ethics Approval Number: NHH/AEC-CL-2017-152A).

Systematic review of commonly used RGs {#sec004}
--------------------------------------

Literature search was carried out in PubMed database(PubMed) \[[@pone.0236338.ref026]\] as detailed in [S5 Fig](#pone.0236338.s014){ref-type="supplementary-material"} according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines \[[@pone.0236338.ref027]\].

### Selection of stable genes {#sec005}

Protein-coding genes identified from 4 publicly available datasets ([Table 1](#pone.0236338.t001){ref-type="table"}), using ensembldb annotation package within R statistical software, were categorised into four quartiles based on their median expression values across all samples. Genes with median expression in middle two quartiles (Q2 and Q3) in all datasets were considered, as Q1 and Q4 representing extreme ends of the expression spectrum are not preferred as RG candidates for normalization of molecular diagnostic markers.

10.1371/journal.pone.0236338.t001

###### List of RNA-seq databases.

![](pone.0236338.t001){#pone.0236338.t001g}

  Dataset                                         Disease            Tissue        Samples (n)                                 Source                                 Download Location
  ----------------------------------------------- ------------------ ------------- ------------------------------------------- -------------------------------------- -------------------------------------------------------------
  TCGA-LAML                                       AML                Blood         151                                         TCGA Research Network                  <https://www.cancer.gov/tcga>
  TARGET-AML                                      Paediatric AML     Bone marrow   159[\*](#t001fn001){ref-type="table-fn"}                                           
  GDC-DLBC[\#](#t001fn003){ref-type="table-fn"}   DLBCL              Lymph nodes   562                                         Schmitz et al 2018^49^                 <https://gdc.cancer.gov/about-data/publications/DLBCL-2018>
  MMRF-MM                                         Multiple Myeloma   Bone marrow   779[^†^](#t001fn002){ref-type="table-fn"}   Multiple Myeloma Research Foundation   <https://research.themmrf.org>

\* Both primary and recurrent tumor

†only 1st visit records.

\# FPKM data for GDC-DLBC dataset was available as log2 transformed normalized value which was converted to FPKM.

To determine the stability of a gene, following statistical measures were employed--(i) CV = $\overline{x}/\sigma_{x}$ where $\overline{x}$ and *σ~x~* are mean and standard deviation of a variable *x* respectively and (ii) normality p-value as measured by Shapiro-Wilks test, where a p-value less than 0.05 signifies that the distribution is away from Normal \[[@pone.0236338.ref028]\]. CV, although used most frequently isn't a robust measure as it is affected by outliers. To solve this, a third parameter was used: MAD (Median Absolute Deviation) = $\left. median \middle| {x - \hat{x}} \right|$ where $\hat{x}$ is the median of *x*, after normalization with median \[[@pone.0236338.ref029]\]. MAD is a better measure for understanding the spread of the distribution as it depends on medians, a parameter, less prone to deviations by outliers.

Low or comparable statistical variation across samples (represented by low values of CV and MAD) and a normal distribution (high value of normality p-value or low values of 1 --p-value) are characteristics of an ideal RG. Therefore genes with median expression values in middle quartiles (Q2 and Q3) were shortlisted and clustered based on their CV, MAD and 1 --p-value (normalized to their respective z-scores) using PAM (Partitioning around Medoids) algorithm \[[@pone.0236338.ref030]\]. Required optimal number of clusters was calculated using Silhouette graphical method \[[@pone.0236338.ref031]\]. For each tissue sample, the gene cluster with the lowest medoid value of parameters was selected and the genes at the intersection of the four clusters were shortlisted \[[@pone.0236338.ref024]\].

The list was further filtered by analysing and eliminating genes based on stop words in their GO (Gene Ontology) annotation such as transcription factors, nuclear receptor or other nuclear localization, DNA binding activity, response to external stimuli, translational and transcriptional activation, since genes with such characteristics regulated by environmental conditions are unsuitable as RG candidates. Next, genes were ranked in ascending order of their mean Euclidean distance $d = \sqrt{{CV}^{2} + {MAD}^{2} + \left( 1 - p \right)^{2}}$ (all parameters replaced by their z-scores) in this three-parameter hyperspace for each dataset. Average of *d* across four datasets was taken to calculate the mean Euclidean distance ($\overline{d}$). Genes with $\overline{d} < median$ were selected for further analysis. Locus of genes associated with pathogenic translocations were identified \[[@pone.0236338.ref032], [@pone.0236338.ref033]\] and candidate RGs in close proximity of such loci (within 10 bands in the same arm of chromosome) were eliminated by an automated method. Further, only genes with non-zero FPKM value in all samples from four datasets were retained. Then, each gene was given a composite quartile ranking (CQR, the sum of quartile indices from each dataset) and genes with CQR value {8, 9, 10} (median expression in 2^nd^ quartile in at least two datasets) were shortlisted ([S6 Fig](#pone.0236338.s015){ref-type="supplementary-material"}).

Design of primers {#sec006}
-----------------

### BCL2 primers {#sec007}

BCL2 has two known splice isoforms: membrane-bound BCL2α and a less studied soluble BCL2β, lacking the trans-membrane domain at the 3' C-terminal \[[@pone.0236338.ref034]\]. Most reported primers amplified only BCL2α or larger amplicon ([S2 Table](#pone.0236338.s002){ref-type="supplementary-material"}), hence new primers were designed ([Table 2](#pone.0236338.t002){ref-type="table"}).

10.1371/journal.pone.0236338.t002

###### Primers details of RGs and BCL2.

![](pone.0236338.t002){#pone.0236338.t002g}

  Primer                                Accession No     Sequence (5\' - 3\')                  Amplicon Length (bp)   Tm (°C)   Amplification Factor
  ------------------------------------- ---------------- ------------------------------------- ---------------------- --------- ----------------------
  **ACY1**                              NM_000666        Fw `5'-CACTGACAACCGCTATATCCG`         106                    60.3      2.05
  Rv `5'-CTCATGCAGCCGTTCATCGT`          62.9                                                                                    
  **ANKRD26**                           NM_014915        Fw `5'-TCTCGGCAAGATCCACAAAGC`         119                    62.7      2.06
  Rv `5'-AATGTAGAGCCGTCCTGTTCA`         60.9                                                                                    
  **JMJD4**                             NM_001161465     Fw `5'-GTCTGTCAATGTCTGTGGGAG`         127                    60        1.99
  Rv `5'-CAGGTGTGTGTCGCAGAGT-3'`        61.9                                                                                    
  **PTCD2**                             NM_024754.5      Fw `5'-TATGGGACACTGCACATCAC-3'`       118                    62        1.99
  Rv `5'-GGCTGACCATCCTCTTGTTTA-3'`      62                                                                                      
  **PPP1R3B**                           NM_024607        Fw `5'-AGAACCTCGCATTTGAGAAGAC-3'`     109                    60.3      1.93
  Rv `5'-TCTGAACCGGCATAAGTGTCC-3'`      61.8                                                                                    
  **FBXW9**                             NM_032301        Fw `5'-TAGGGCGGTGCGATGATTC-3'`        117                    61.9      1.99
  Rv `5'-CGGATTTTGGCGGACTGAGA-3'`       62.2                                                                                    
  **NANP**                              NM_152667.3      Fw `5'-GGTCCGCCTACTTCTATTAACG-3'`     112                    62        1.98
  Rv `5'-TCTCTGCTCTCCACCTACAA-3'`       62                                                                                      
  **PLEKHM3**                           NM_001080475.3   Fw `5'-GATGATATCAGCCCAGCCTTAG-3'`     109                    62        1.94
  Rv `5'-GGACTTCCTGGATCCCATAAAC-3'`     62                                                                                      
  **TSGA10**                            NM_025244        Fw `5'-TACTCAGCGACACCTTGCTAA-3'`      152                    60.9      2
  Rv `5'-CCAGATCATTGAGGGTTCCAC-3'`      60.1                                                                                    
  **NAT1**                              NM_001160174     Fw `5'-GGGAGGGTATGTTTACAGCAC-3'`      128                    60.1      1.8
  Rv `5'-ACATCTGGTATGAGCGTCCAA-3'`      60.9                                                                                    
  **RIC8B**                             NM_018157        Fw `5'-ATAGTGTTCAACAGTCAGATGGC-3'`    133                    60.3      1.92
  Rv `5'-GCAAGCGCAAGTCAAAGCA-3'`        62.2                                                                                    
  **GAPDH**                             NM_001289745.3   Fw `5'-TCGACAGTCAGCCGCATCTTCTTT-3'`   196                    59        1.95
  Rv `5'-GCCCAATACGACCAAATCCGTTGA-3'`   60                                                                                      
  **BCL2**                              NM_000657.2      Fw `5'-GGAGGATTGTGGCCTTCTTT-3'`       113                    62        1.89
  Rv `5'-GCCCAATACGACCAAATCCGTTGA-3'`   60                                                                                      

Fw: Forward primer; Rv: Reverse primer.

### RG primers {#sec008}

Primers for shortlisted genes were designed ([Table 2](#pone.0236338.t002){ref-type="table"}; [S3 Table](#pone.0236338.s003){ref-type="supplementary-material"}) using PrimerBank \[[@pone.0236338.ref035]\] and IDT \[[@pone.0236338.ref036]\].

Sample details {#sec009}
--------------

RNA was isolated from peripheral blood or bone marrow samples from patient or normal individuals ([S7 Fig](#pone.0236338.s016){ref-type="supplementary-material"}) with their informed consent (Ethics Approval Number: NHH/AEC-CL-2017-152A). Subjects with Hepatitis B/C or HIV, and pregnant or lactating women were excluded from the study.

PBMC/BMMC (Peripheral Blood Mononuclear cells/ Bone Marrow mononuclear cells) were separated by layering 1:1 of blood or bone marrow (diluted to 1:3 with 1X PBS Gibco™, Germany) above Ficoll-Paque Plus Histopaque, (HiMedia, India) followed by centrifugation at 400 RCF for 25 Mins with brakes off. Resultant buffy coat was washed twice with 1X PBS and once with 1X PenStrep (HiMedia, India) before culturing at cell density of 0.5 to 0.8 million cells/mL of RPMI 1640 (HiMedia, India) with 20% FBS (Gibco™, Germany, Brazil origin) and 1X PenStrep for subculturing the lymphocyte population.

RNA, cDNA and qPCR {#sec010}
------------------

From FFPE (Formalin-fixed, paraffin-embedded) blocks, 5--8 curls were deparaffinized in xylene at 50°C, followed by proteinase K (HiMedia, India) treatment prior to RNA isolation. Either from lymphocytes or from deparaffinized retrospective samples \[[@pone.0236338.ref037]\] RNA was isolated by TRIzol™ (Ambion, US) method and quantified with Qubit RNA BR Assay Kit (Thermo Fisher Scientific, US) before converting to cDNA using SuperScript IV (SSIV, Thermo Fisher Scientific, US) as per manufacturers' instructions. With no-template control (NTC), qPCR was performed in triplicates for each sample using KAPA SyBr green Universal reagents (Sigma Aldrich, US), cDNA (1:10 dilution) and primers in a 5μL reaction mix (qPCR condition: pre-incubation at 95°C for 10 minutes followed by amplification for 40 cycles--denaturation at 95°C for 10 sec, amplification at 60°C for 15 sec, and extension at 72°C for 15 sec) in Roche LightCycler 480 II machine.

Optimization of primers {#sec011}
-----------------------

Primers were optimized for qPCR as required by the MIQE guidelines \[[@pone.0236338.ref038]\]. All primers were used at four different final concentrations (forward/reverse): 200nM/200nM; 200nM/100nM; 100nM/200nM and 100nM/100nM with pooled cDNA template, obtained from six normal healthy volunteers to yield single amplification product. Primer efficiency was checked using a two-fold five-point dilution of the template. Primer efficiency was obtained from standard curve using the formula: $Amplication\ Factor = \left( 10^{- \frac{1}{slope}} - 1 \right) \times 100$ ([Table 2](#pone.0236338.t002){ref-type="table"}).

Stability analysis of candidate RGs {#sec012}
-----------------------------------

Mean of Cq (Quantification cycle) of NTC were subtracted from Cq values of each gene in qPCR experiments to obtain ΔCq = *Cq* (*sample*)−*Mean Cq* (*NTC*) and relative expression as *E*^−ΔCq^ for each replicate, where E is the amplification factor of corresponding gene.

Stability of expression of the candidate RGs was analysed using three independent algorithms--geNorm \[[@pone.0236338.ref039]\], NormFinder \[[@pone.0236338.ref040]\] and BestKeeper \[[@pone.0236338.ref041]\] and the web-based RefFinder tool \[[@pone.0236338.ref042]\] that integrates all three algorithms plus the delta CT method. Algorithm geNorm was run using the SLqPCR R package \[[@pone.0236338.ref043]\], whereas author-supplied R package and Excel worksheet were used for NormFinder and BestKeeper analysis respectively. Mean Cq values for each gene for all 78 samples were used as input for BestKeeper and RefFinder, whereas for geNorm and NormFinder relative expression values were used. Since NormFinder uses a model-based approach to quantify inter- and intra-group variations, the malignant and non-neoplastic or healthy-normal samples were used as two groups for NormFinder analysis.

Comprehensive stability rank of each gene was calculated as the geometric mean of stability rank given by each method.

Expression analysis of BCL2 {#sec013}
---------------------------

RQ (Relative Quantification) of BCL2 expression was calculated either as ratio of relative expression of BCL2 with relative expression of GAPDH or the normalization factor which is geometric mean of relative expression of three candidate RGs: $$RQ\ \left( {GAPDH} \right) = E^{- \Delta Cq}\left( {BCL2} \right)/E^{- \Delta Cq}\left( {GAPDH} \right)$$ $${RQ\ \left( {proposed} \right) = E}^{- \Delta Cq}\left( {BCL2} \right)/{Geo\ Mean\ E}^{- \Delta Cq}\left( {PTCD2,PPP1R3B,FBXW9} \right)$$

Results and discussion {#sec014}
======================

Quantification by qPCR could be the choice of pathology laboratories for a quick and cost-effective platform for single-gene expression level, with appropriate RG. Towards this effort, MacRae et al (2013) \[[@pone.0236338.ref021]\] performed a genome wide search and statistical analysis using RNA-seq data from 55 leukemia patients. In a more recent pan-cancer study \[[@pone.0236338.ref022]\], publicly available gene expression data from 193 microarray studies were analysed to identify a few RG candidates that showed minimal variation between malignant and normal samples and were validated in droplet digital PCR on bone marrow samples of ALL patients. We have used 6 types of haematological malignancy samples encompassing bone marrow, PBMC and FFPE blocks along with non-neoplastic bone marrow and healthy PBMC samples subsequent to using much wider publicly available data from 1,651 samples in AML, DLBCL and multiple myeloma databases. Further, we have employed an improved statistical analysis including clustering technique described in Methods section. Instead of an ad hoc approach of selection of top few genes from the clusters, we used important biological considerations to further prune the list of candidate RGs.

Systematic review of commonly used RGs from literature {#sec015}
------------------------------------------------------

Systematic Review of 122 articles yielded 43 RGs used in haematological malignancies through (a) selection of genes by different analysis methods ([S4 Table](#pone.0236338.s004){ref-type="supplementary-material"}) and (b) usage of known RGs in qPCR ([S1 Table](#pone.0236338.s001){ref-type="supplementary-material"}). FPKM values of all these RGs when examined in 4 public databases showed varied expression among different types of haematological malignancies ([S3](#pone.0236338.s012){ref-type="supplementary-material"} and [S4](#pone.0236338.s013){ref-type="supplementary-material"} Figs) with maybe the exception of PGGT1B \[[@pone.0236338.ref022]\]. However, since other genes selected in the literature showed higher expression and correlated extreme variation, we could not depend on the assay and proceeded to select novel RGs with an unbiased approach.

Selection of candidate RGs {#sec016}
--------------------------

### Statistical analysis {#sec017}

Stepwise filtration of the number of genes from each dataset is summarized in [S6 Fig](#pone.0236338.s015){ref-type="supplementary-material"} and also in Graphical Abstract. [Fig 1](#pone.0236338.g001){ref-type="fig"} shows gene clusters plotted in CV, normalized MAD and 1-p-value hyperspace for four datasets. Cluster marked in green in each figure represents the cluster with least medoid value ([S5 Table](#pone.0236338.s005){ref-type="supplementary-material"}) for the three parameters. Selected clusters in the four datasets had an overlap of 1961 genes, indicating large number of genes involved in housekeeping processes and hence showing lesser inter-sample variation across diverse datasets. Common genes were pruned further to 541 by GO biological process term filtration, disease association and CQR to lead to a final of 19 genes ([S6 Table](#pone.0236338.s006){ref-type="supplementary-material"}) that were taken through experimental validation. Melt curve analysis and efficiency check with pooled cDNA from six healthy volunteers narrowed it down to 11 genes with stable median expression and single amplification product of expected size for each ([Table 2](#pone.0236338.t002){ref-type="table"}). Primers for genes which did not qualify the efficiency check were eliminated as they failed to show single amplification peak after repeated trials with new experimental conditions and even new primer sequences ([S3 Table](#pone.0236338.s003){ref-type="supplementary-material"}).

![Statistical analysis of candidate genes.\
Genes plotted in the CV, normalized MAD and (1 --p-value) hyperspace for the four datasets (A) TCGA-LAML, (B) TARGET-AML, (C) GDC-DLBC and (D) MMRF-MM. Cluster shown in green represents the chosen cluster with least value of medoids.](pone.0236338.g001){#pone.0236338.g001}

Expression of 11 genes with efficient primers were analysed on 78 samples by qPCR. Using observed Cq values preliminary stability analysis of the 11 genes were done with online RefFinder tool to select top 10 stable genes (PTCD2, PPP1R3B, FBXW9, NANP, RIC8B, JMJD4, PLEKHM3, NAT1, ANKRD26, TSGA10) as RG candidatessss.

### Stability analysis of candidate RGs {#sec018}

Results of BestKeeper algorithm, used independently or as part of RefFinder were comparable whereas results of geNorm or Normfinder analysis differed as they used different inputs. Geometric mean of stability ranks assigned in each algorithm was used to create comprehensive stability ranking of all the candidate RGs ([S7 Table](#pone.0236338.s007){ref-type="supplementary-material"} and [Fig 2](#pone.0236338.g002){ref-type="fig"}). The analysis shows PTCD2, PPP1R3B and FBXW9, to be most stable across all analysed patient samples.

![Stability rank of candidate reference genes.](pone.0236338.g002){#pone.0236338.g002}

PTCD2 (Pentatricopeptide repeat-containing protein 2) codes for a mitochondrial protein, involved in RNA binding, maturation and respiratory chain function though its exact molecular function is not well understood \[[@pone.0236338.ref044], [@pone.0236338.ref045]\]. PPP1R3B (Protein phosphatase-1 regulatory-subunit-3B) encodes for a catalytic subunit phosphatase 1 regulatory subunit 3B, which is involved in hepatic glycogen dysregulation in Type 2 diabetes \[[@pone.0236338.ref046]--[@pone.0236338.ref048]\] FBXW9 (F-box/WD repeat-containing protein 9) is a cytosolic protein involved in ubiquitination and proteasome degradation \[[@pone.0236338.ref049]\].

Expression analysis of BCL2 {#sec019}
---------------------------

Accurate determination of BCL2 expression among few anti-apoptotic markers in patients with haematological malignancies is emerging as a critical diagnostic test for clinicians to suggest efficacious therapy options. FPKM values of 8 RGs (5 common and 3 novel) from the publicly available databases when compared ([Fig 3](#pone.0236338.g003){ref-type="fig"}) with BCL2 indicated the novel RGs to be better normalization candidate for BCL2 in qPCR assays in pathology labs due to less and stable expression.

![Candidate reference genes in hematological malignancy datasets.\
Expression values of candidate genes in four datasets (A) TCGA-LAML, (B) TARGET-AML, (C) GDC-DLBC and (D) MMRF-MM.](pone.0236338.g003){#pone.0236338.g003}

Comparison of relative expression of GAPDH versus the proposed normalization factor (geometric mean of relative expression of the three RG candidates) clearly show a large variation in GAPDH expression (0--2^15^) across malignant samples ([Fig 4A](#pone.0236338.g004){ref-type="fig"}; [S8 Table](#pone.0236338.s008){ref-type="supplementary-material"}). Granted its popularity, the expression stability of GAPDH has been proven to differ in different conditions due to its involvement in apoptotic cell death through ubiquitin ligase \[[@pone.0236338.ref050]\], membrane trafficking \[[@pone.0236338.ref051]\], upregulation in AML \[[@pone.0236338.ref052]\], involvement in Non-Hodgkin's B-cell Lymphomas \[[@pone.0236338.ref053]\] and inconsistency in several other cancers \[[@pone.0236338.ref054]\]. On the other hand, proposed RGs have lesser variation (0--2^10^) and their expressions are consorted with each other making them better candidate as RG compared to GAPDH. This behaviour is translated to BCL2 expression RQ in malignant samples when normalized with GAPDH ([Fig 4B](#pone.0236338.g004){ref-type="fig"}). Evidently, normalization with GAPDH underestimates relative quantification of BCL2 compared to normalization with proposed RGs, with a statistically significant difference in median values (p \< 0.01, Wilcoxon rank sum test) between the two schemes. BCL2 quantification in haematological malignancies by qPCR is overtly reliant on RG since availability of "adjacent normal" sample is ruled out. Above results clearly demonstrate how the quantification may go off limit due to a wrong choice of RG.

![Relative expression of chosen reference genes and relative quantification of BCL2.\
(A) Relative expression of chosen reference genes (solid lines) and GAPDH (dashed line) across patient samples. (B) Relative Quantitation of BCL2 expression with respect to the candidate reference genes and GAPDH in malignant patient samples.](pone.0236338.g004){#pone.0236338.g004}

Broader applicability of proposed reference genes {#sec020}
-------------------------------------------------

Though primary objective of this study is to discover RG candidates for BCL-2 diagnostics in a clinical setting, the RGs may have broader utility in other experimental platforms or model systems. In the systematic review we found a number of research articles \[[@pone.0236338.ref055]--[@pone.0236338.ref062]\] that have used TaqMan probes instead of SYBR green, whereas our validation experiment was carried out using SYBR green probes. However, studies in different contexts such as a tropical oilseed plant \[[@pone.0236338.ref063]\], or measurement of expression of various adenosine receptors in breast cancer tissue \[[@pone.0236338.ref064]\] and in experiments using human reference RNA \[[@pone.0236338.ref065]\], SYBR green PCR assays were observed having fair concordance with TaqMan PCR. From these evidences, we believe that stability of proposed RGs is not likely to differ between SYBR green and TaqMan qPCR assays.

To assess variation of these stable RGs in cell lines, we analyzed RPKM values of 18,778 protein-coding genes across 173 cell lines of haematopoietic and lymphoid tissue origin from Broad Institute Cancer Cell Encyclopedia \[[@pone.0236338.ref066]\] and found the proposed RGs presenting much lesser variations in expression compared to the 5 common RGs (GAPDH, ABL1, B2M, GUSB and ACTB) in cell lines as well ([S8 Fig](#pone.0236338.s017){ref-type="supplementary-material"}).

Both transgenic and wild type and occasional rat models are widely used in leukemia and lymphoma research \[[@pone.0236338.ref067], [@pone.0236338.ref068]\]. Usability of RGs common between clinical and animal studies will thus be of immense advantage. We find that the proposed RGs--PTCD2, PPP1R3B and FBXW9 have 70--90% sequence similarity and identity with corresponding genes in mice and other commonly used rodent models ([S9 Table](#pone.0236338.s009){ref-type="supplementary-material"}), suggesting the genes playing similar role in cellular function thereby displaying stability, similar to that in humans. Hence normalization factor derived from the expression of these RGs may be applicable in murine and other rodent models as well with suitable design of primers encompassing conserved regions.

Beyond detection of gene expression at mRNA level, it may be worthwhile to explore the applicability of protein counterpart of the stable RGs in Western Blot as control for protein detection. By design, we have chosen RGs that are of moderate expression level (in middle quartiles of expression among other genes), and they may not be detectable by Western blot unless a larger amount of sample is loaded, which is often not feasible with clinical samples. However, it may be an interesting proposition to predict stable reference proteins for use in Western blot by statistical analysis of proteomics data and associated systematic review of literature.

Conclusion {#sec021}
==========

Our results indicate that genes PTCD2, PPP1R3B and FBXW9 render more reliability to qPCR-based diagnostic test of BCL2 in haematological malignancies. The conclusion can be extended to other biomarkers in liquid cancer as well as for research with other model systems such as cell lines and rodents.
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PONE-D-20-15589

Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference

PLOS ONE

Dear Dr. das,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please make sure you address issues relating to inter-gene normalization and, considering that expression levels depend seriously on the choice of reference gene, authors must address the need for normalization of these parameters. Namely, the inter-gene normalization approach for reference gene - at best with support of data retrieved from comparing these reference genes.

Please submit your revised manuscript by Jul 27 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Pedro V. Baptista, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to 'Update my Information' (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: <https://www.youtube.com/watch?v=_xcclfuvtxQ>

Additional Editor Comments (if provided):

Authors should carefully provide response to the Reviewers\' queries. Particularly, attention must be paid to the normalization factor and how to apply the same rationale to other relevant genes involved in the condition. Careful observation of the inter-gene variations and how to reduce impact in variation in quantifying gene expression must be taken into account.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The manuscript submitted by Dwivedi et al screened out three stable uncontrolled reference genes for qPCR analysis of BLC2 mRNA. The authors validated the significance and applicability of PTCD2, PPP1R3B and FBXW9 across lymph-nodes, bone marrow and PBMC samples after massive statistic analysis. The methodology established here demonstrates a compelling and professional approach to addressing the issues in quantifying expression of BCL2 levels of hematological malignancies in the clinics. Therefore, the results presented here indicated much advancement in this field and would be of great interest to a large number of readers. I would support the publication of this well-written manuscript in PLOS One after minor revision.

1\. Would these screened out reference genes be stable in cell lines, other than primary cells?

2\. Have the authors compared or noticed any difference between Taqman and SyBr green in qPCR when determining the stability of reference genes?

3\. Would the western blot assay reflect similar results using these three stable reference genes?

4\. How about the applicability of these three reference genes in animal model or murine cells?

Reviewer \#2: Dysregulation of the B-cell leukemia/lymphoma-2 (BCL-2) family of proteins of the intrinsic apoptotic pathway is fundamental to the pathophysiology of many hematologic malignancies. BCL-2 dysregulation enables cells that would normally undergo apoptosis to survive. Targeting BCL-2 has been the goal of various initiatives, and some are in clinical trials and for example Venetoclax was approved by the US Food and Drug Administration for the treatment of patients with CLL who have 17p deletion. This article sought to assess the reliability of several Reference Genes (RG) in the quantification of BCL-2 expression in haematological malignancies. RGs are indispensable for normalizing mRNA levels across samples in real-time quantitative PCR. As their expression levels vary under different experimental conditions, appropriate reference gene selection is thus critical for gene-expression studies. As such the work has merit.

The authors found a set of novel candidate RGs obtained from an unbiased search of \>60,000 genes in haematological malignancies to normalize BCL2 and other anti-apoptotic genes in qPCR. The workflow was thorough, and included looking at publicly available datasets and most importantly, experimental validation in a series of patient samples. The analysis shows PTCD2, PPP1R3B and FBXW9 to be most stable genes across all patient samples.

Reference to past publications underlining the importance of a correct selection of appropriate RGs is needed. The use of an inappropriate reference gene may lead to erroneous normalization and flawed conclusions. Given that no universal reference gene exists with a constant expression in all tissues and cell types, reference genes need to be selected and validated for each specific application. The use of more than one reference gene and even gene panels has been recommended to overcome variations in individual gene expression. This should be stressed in the article. Examples of articles are given below.

Radonić, A., Thulke, S., Mackay, I. M., Landt, O., Siegert, W., & Nitsche, A. (2004). Guideline to reference gene selection for quantitative real-time PCR. Biochemical and biophysical research communications, 313(4), 856-862.

Dheda, K., Huggett, J. F., Chang, J. S., Kim, L. U., Bustin, S. A., Johnson, M. A., \... & Zumla, A. (2005). The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Analytical biochemistry, 344(1), 141-143.

As discussed by Vandesompele et al., in order to measure expression levels accurately, normalization by multiple housekeeping genes instead of one is required. Consequently, a normalization factor based on the expression levels of the best-performing housekeeping genes must be calculated. This has not been done in this article, therefore the authors are urged to present normalization factors with the RGs they identified and present the results.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Reviewer's comment on "Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference" by Dwivedi et al submitted to PLOS ONE

Responses to Reviewer 1 comments

R1.1. Would these screened out reference genes be stable in cell lines, other than primary cells?

Response: We thank the reviewer for bringing up this aspect. We checked expression of these reference genes in cell lines of haematopoietic and lymphoid tissue origin from Broad Institute Cancer Cell Encyclopaedia and found them to show lesser variations compared to common reference genes (GAPDH, ABL1, B2M, GUSB and ACTB) in cell lines as well. These results are added in revised manuscript (Results and Discussions: lines 262-268) and in supplementary data (Fig S8).

R1.2. Have the authors compared or noticed any difference between Taqman and SyBr green in qPCR when determining the stability of reference genes?

Response: We have not performed any experiment comparing stability of the reference genes between TaqMan and SYBR green probes. While performing the systematic review we came across a number of research articles \[1--8\] that have used TaqMan probes, but none of them present a comparison with SYBR green.

However, we came across other studies that have compared the assay using TaqMan and SYBR green probes. Cao and Shockey \[9\] demonstrated identical expression patterns of reference genes between SYBR Green and TaqMan qPCR for a tropical oilseed plant whereas Tajadini et al \[10\] measured the expression of various adenosine receptors in breast cancer tissue and found performance of the SYBR green assay as comparable with TaqMan. In a different context using human reference RNA, Arikawa et al \[11\] found SYBR green PCR assays having maximum concordance with TaqMan PCR.

From these evidences, we believe that stability of reference genes are not likely to differ in SYBR green qPCR assay compared to TaqMan. Hence, we have not commented on this aspect in our revised manuscript.

R1.3. Would the western blot assay reflect similar results using these three stable reference genes?

Response: Our study focuses on detection of BCL2 through qPCR for diagnostic purposes, hence aiming at only the mRNA expression of genes.

By design we have chosen reference genes that are of moderate expression level (in middle quartiles of expression among other genes), and they may not be detectable by Western blot unless a larger amount of sample is loaded, which is often not feasible with clinical samples.

Having said that, it may be an interesting proposition to predict stable reference proteins for use in Western blot. For this a new study can be initiated with statistical analysis of proteomics data and associated systematic review of literature.

R1.4. How about the applicability of these three reference genes in animal model or murine cells?

Response: This a very relevant comment as use of animal models, especially murine models are very common in leukemia and lymphoma research. We analyzed sequences of the proposed reference genes and found them to have 70 -- 90% similarity and identity with corresponding genes in mouse or other rodent models. This result indicates that proposed reference genes may also be useful in experiments with murine models.

We have incorporated these results in revised manuscript (Results and discussion: lines 269 -- 277) and in supplementary data (Table S8). We thank the reviewer for bringing out this perspective.

Responses to Reviewer 2 Comments

R2.1. Reference to past publications underlining the importance of a correct selection of appropriate RGs is needed.

Response: We had mentioned about inconsistency in GAPDH expression as reported in literature in the Results and discussion section (lines 303 -- 306). However, as suggested by reviewer we have added a paragraph on this topic (Introduction: lines 64-72) adding reference to past publications. We thank the reviewer for this valuable suggestion.

R2.2. The authors are urged to present normalization factors with the RGs they identified and present the results.

Response: Normalization factor as mentioned by reviewer refers to geometric mean of relative expression of the reference genes. We had already used this in our calculations for BCL2 relative quantitation.

However, based on reviewer's suggestion we have explicitly mentioned the normalization factor in appropriate places of the manuscript (Materials and methods: lines 199-204, Results and discussion: lines 300-301 and Fig. 4). We have also added a table with values of normalization factors in the supplementary data (Table S9).
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PLOS ONE

Dear Dr. das,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Authors are requested to introduce into the manuscript two minor discussion points that were provided in the response to the Referees

1- the brief clarification on SYBR green (the discussion text in the Response letter should suffice)

2- the point on the focus on mRNA expression and referring the correlation to protein expression (as measured by Western blot) - again, the discussion text in the Response letter should suffice.

Please submit your revised manuscript by Aug 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Pedro V. Baptista, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (if provided):

Authors are requested to introduce two minor discussion points that were provided in the response to the Referees

1- the brief clarification on SYBR green (the discussion text in the Response letter should suffice)

2- the point on the focus on mRNA expression and referring the correlation to protein expression (as measured by Western blot) - again, the discussion text in the Response letter should suffice.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have greatly revised the manuscript and improved its overall qualify. My questions have been well addressed. I would recommend it for publication in PLOS one.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to Editor's comments on "Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference" by Dwivedi et al submitted to PLOS ONE

Editor's comments:

Authors are requested to introduce into the manuscript two minor discussion points that were provided in the response to the Referees

1- the brief clarification on SYBR green (the discussion text in the Response letter should suffice)

2- the point on the focus on mRNA expression and referring the correlation to protein expression (as measured by Western blot) - again, the discussion text in the Response letter should suffice.

Response:

We thank Editor for the suggestion to introduce above discussion points in the manuscript which has further elevated the value of our work. In line with this suggestion, we have introduced a new subsection "Broader applicability of proposed reference genes" under Results and Discussion and included discussion points on SYBR green (lines 310 -- 319), cell lines (lines 320 - 324), rodent models (lines 325- 333) and Western blot (lines 334 - 341) in this subsection. We think all these discussion points being under same subsection makes the flow more coherent.
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PONE-D-20-15589R2

Dear Dr. das,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Pedro V. Baptista, PhD

Academic Editor

PLOS ONE

10.1371/journal.pone.0236338.r006
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13 Jul 2020

PONE-D-20-15589R2

Relative quantification of BCL2 mRNA for diagnostic usage needs stable uncontrolled genes as reference

Dear Dr. Das:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Pedro V. Baptista

Academic Editor

PLOS ONE
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